Qimeng Yin

Abstract Sepsis-induced excessive inflammation contributes to mortality, but restricting hyperinflammation in sepsis remains challenging. Here, we identify dipeptidase 2 (DPEP2) as an immunotherapeutic target in sepsis by integrating single-cell and bulk RNA sequencing data from septic patients. In patients with sepsis, peripheral monocytes/macrophages have reduced DPEP2 expression, with DPEP2 levels negatively correlating with inflammation severity, disease progression, and clinical outcomes.

1 Introduction The COVID-19 pandemic has highlighted the transformative potential of mRNA technology, exemplified by the clinical success of Pfizer-BioNTech and Moderna's mRNA vaccines.[1-3] These vaccines have shown unprecedented clinical efficacy in preventing COVID-19, primarily due to their ability to rapidly induce robust immune responses.[1, 4] This success has catalyzed the development of mRNA-based cancer vaccines as a promising strategy for eliciting potent and specific anti-tumor...

Keywords in vivo CAR off-the-shelf CAR panCAR immunotherapy circRNA vaccine RNA therapeutics Introduction Chimeric antigen receptor (CAR) T cell therapy is an important method of cancer immunotherapy that has successfully treated hematologic malignancies, particularly B lymphomas.1 However, CAR-T cell therapy still faces several challenges, including high costs, a time-consuming manufacturing process, the necessity of lymphodepletion, and side effects such as cytokine storm and on-target,...